Neuroendocrine tumors refer to a group of cancers that originate from neuroendocrine cells of the body. These tumors can develop in several organs like lungs, pancreas, intestine and stomach. Common symptoms include easy bruising, abdominal pain, flushing or diarrhea. Treatment for neuroendocrine tumors majorly includes surgery to remove the tumor, radiation therapy to kill cancer cells and prevent tumor growth. Chemotherapy involves use of drugs like streptozotocin and 5-fluorouracil to destroy cancer cells. Some hormonal therapies aim to slow or stop tumor growth by blocking certain hormones. Targeted drug therapies such as sunitinib and everolimus intervene specific pathways that help cancer cells grow and spread.
The Global Neuroendocrine Tumor Treatment Market is estimated to be valued at US$ 3.46 Bn in 2024 and is expected to exhibit a CAGR of 8.5% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the Neuroendocrine Tumor Treatment are Schott AG, Yulong Dingtajian, Apex Solar, Sinosun Energy, Neo Solar Power Corporation, Solimpeks Solar Energy, Sunrain, Hubei Fullhonor Solar Energy, and others. With rising global incidence of neuroendocrine tumors, the need for effective treatment options is growing significantly. Some major players are focusing on development of targeted drug therapies to prevent tumor growth and metastatic spread.
Growing demand in the market: The Neuroendocrine Tumor Treatment Market Trends is rising primarily due to increasing incidence of neuroendocrine tumors worldwide. According to estimates, neuroendocrine tumors annually affect around 5 people per 100,000. This unmet medical need is a major factor boosting adoption of newer targeted therapies and combination regimen over conventional chemotherapy.
Global expansion of market: Key neuroendocrine tumor treatment manufactures are expanding their geographical presence through collaboration with local distribution partners. For instance, In 2022, Solimpeks Solar Energy entered into partnership with a South African company to distribute its products in Africa. This helped enhance accessibility of neuroendocrine tumor therapies in new potential markets.
Market key trends
The increased research in targeted drug therapies is a key trend witnessed in the neuroendocrine tumor treatment market. Many pharmaceutical companies are involved in development of small molecule inhibitors focused on receptor tyrosine kinases and mTOR pathways. Agents like Cabozantinib, Olaparib and Sorafenib shows promising results in clinical trials and are expected to be available soon for treatment against specific neuroendocrine tumor types.
Porter’s Analysis
Threat of new entrants: New pharmaceutical and biotechnology companies face significant challenges in entering this market due to high capital requirements and stringent regulatory approvals.
Bargaining power of buyers: Individual consumers have low bargaining power as they seek access to novel and effective therapies to improve treatment outcomes.
Bargaining power of suppliers: Suppliers of pharmaceutical ingredients and raw materials have moderate bargaining power as there exist substitutes and buyers negotiate prices and contracts.
Threat of new substitutes: Emerging therapies for NETs represent potential substitutes but have not demonstrated superiority to existing options.
Competitive rivalry: Competition among established pharmaceutical companies is strong as they invest in R&D to introduce innovative drugs and combination therapies that improve patient outcomes.
Geographically, North America dominates the neuroendocrine tumor treatment market in terms of value. This is attributed to high awareness regarding rare cancers, favorable reimbursement policies for innovative therapies, easy regulatory pathways for clinical trials, and presence of key market players. Asia Pacific represents the fastest growing regional market for NET therapies owing to increasing burden of NETs, rising healthcare expenditure, and growing popularity of precision cancer treatments.
Get More Insights on- Neuroendocrine Tumor Treatment Market
About Author:
Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement.
(LinkedIn- https://www.linkedin.com/in/priya-pandey-8417a8173/)
Comments
0 comment